Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome.

Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, Ginger M, Frick A, DiPatrizio NV, Mackie K, Katona I, Piomelli D, Manzoni OJ.

Nat Commun. 2012;3:1080. doi: 10.1038/ncomms2045.

2.

Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia.

Gregg LC, Jung KM, Spradley JM, Nyilas R, Suplita RL 2nd, Zimmer A, Watanabe M, Mackie K, Katona I, Piomelli D, Hohmann AG.

J Neurosci. 2012 Jul 11;32(28):9457-68. doi: 10.1523/JNEUROSCI.0013-12.2012.

3.

Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex.

Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni OJ.

PLoS One. 2007 Aug 8;2(8):e709.

4.

A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization.

Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D.

Mol Pharmacol. 2007 Sep;72(3):612-21.

5.

Dysregulation of mTOR signaling in fragile X syndrome.

Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, Zukin RS.

J Neurosci. 2010 Jan 13;30(2):694-702. doi: 10.1523/JNEUROSCI.3696-09.2010.

6.
7.

Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA.

Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Musella A, Bernardi G, Bagni C, Centonze D.

Neuropsychopharmacology. 2010 Jun;35(7):1500-9. doi: 10.1038/npp.2010.19.

8.

Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.

Ronesi JA, Collins KA, Hays SA, Tsai NP, Guo W, Birnbaum SG, Hu JH, Worley PF, Gibson JR, Huber KM.

Nat Neurosci. 2012 Jan 22;15(3):431-40, S1. doi: 10.1038/nn.3033.

9.

Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia.

Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I.

Eur J Neurosci. 2009 May;29(10):1964-78. doi: 10.1111/j.1460-9568.2009.06751.x.

10.

Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse.

Ronesi JA, Huber KM.

Sci Signal. 2008 Feb 5;1(5):pe6. doi: 10.1126/stke.15pe6. Review.

PMID:
18272470
12.

Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse.

Higashimori H, Morel L, Huth J, Lindemann L, Dulla C, Taylor A, Freeman M, Yang Y.

Hum Mol Genet. 2013 May 15;22(10):2041-54. doi: 10.1093/hmg/ddt055.

13.

A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome.

Giuffrida R, Musumeci S, D'Antoni S, Bonaccorso CM, Giuffrida-Stella AM, Oostra BA, Catania MV.

J Neurosci. 2005 Sep 28;25(39):8908-16.

14.

Molecular reorganization of endocannabinoid signalling in Alzheimer's disease.

Mulder J, Zilberter M, Pasquaré SJ, Alpár A, Schulte G, Ferreira SG, Köfalvi A, Martín-Moreno AM, Keimpema E, Tanila H, Watanabe M, Mackie K, Hortobágyi T, de Ceballos ML, Harkany T.

Brain. 2011 Apr;134(Pt 4):1041-60. doi: 10.1093/brain/awr046.

15.

Targeting the endocannabinoid system in the treatment of fragile X syndrome.

Busquets-Garcia A, Gomis-González M, Guegan T, Agustín-Pavón C, Pastor A, Mato S, Pérez-Samartín A, Matute C, de la Torre R, Dierssen M, Maldonado R, Ozaita A.

Nat Med. 2013 May;19(5):603-7. doi: 10.1038/nm.3127.

PMID:
23542787
16.

Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome.

Zhang L, Alger BE.

J Neurosci. 2010 Apr 21;30(16):5724-9. doi: 10.1523/JNEUROSCI.0795-10.2010.

17.

Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome.

Dölen G, Bear MF.

J Physiol. 2008 Mar 15;586(6):1503-8. doi: 10.1113/jphysiol.2008.150722. Review.

18.

S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade.

Narayanan U, Nalavadi V, Nakamoto M, Thomas G, Ceman S, Bassell GJ, Warren ST.

J Biol Chem. 2008 Jul 4;283(27):18478-82. doi: 10.1074/jbc.C800055200.

19.

The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain.

Aschrafi A, Cunningham BA, Edelman GM, Vanderklish PW.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2180-5.

20.

Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome.

Costa L, Spatuzza M, D'Antoni S, Bonaccorso CM, Trovato C, Musumeci SA, Leopoldo M, Lacivita E, Catania MV, Ciranna L.

Biol Psychiatry. 2012 Dec 1;72(11):924-33. doi: 10.1016/j.biopsych.2012.06.008.

PMID:
22817866

Supplemental Content

Support Center